Irritable Bowel Syndrome Treatment Market Size, Share | Industry Report, 2026

The Global Irritable Bowel Syndrome Treatment Market is estimated to cross Market Size of US$ 3.4 Billion by 2026 with a CAGR of 9.8% during the forecast period 2019 to 2026.

The growing incidence of target diseases and the expansion of current medicines labels are expected to accelerate market growth. Furthermore, increasing use of medicines and the launch of new goods are expected to drive the market for IBS (Irritable Bowel Syndrome).

IBS is one of the most popular gastrointestinal illnesses with a incidence of 10-15% globally. Most IBS individuals are under the age of 50 but many elderly people also suffer. The impact of this disease may range from mild discomfort to severe weakness. It can regulate several aspects of the professional, emotional and social lives of a patient. Moderate to serious patients typically have symptoms which often adversely affect their mental, physical, educational, social, and financial well-being.

Symptoms may differ, and constipation may alternate with diarrhea, sometimes contradictory. These variables add to the need for irritable bowel syndrome treatments which allow patients to continue with their daily lives. The syndrome of long term patients is likely to disrupt their private and professional operations, and normally limits their potential.

Roughly 40% of patients suffer from mild IBS, 35% have moderate IBS, and 25% have serious IBS. Many individuals are unable to differentiate between IBS symptoms; it is still one of the most frequent illnesses that doctors are diagnosed. Not all people with IBS symptoms have the same therapy. However, approximately 2.4 to 3.5 million doctor calls are given annually in the United States alone for irritable bowel syndrome. It impacts approximately 35–40% of men and 60%–65% of women worldwide.

Free Download Sample Report Pages for Better understanding@ https://www.acumenresearchandconsulting.com/request-sample/1528

Key Highlights

Due to the increasing incidence and increasing intake of medication such as Linzess / Constella and Amitiza, IBS-C was the biggest producing income segment per form in 2018.

Due to increased product acceptance in significant areas like the U.S., Germany, U.K., Italy, Spain, and Japan, Linzess / Constella was in 2018 the market leader on the worldwide IBS therapy market.

The biggest income-generating region in 2018, North America was projected to be, followed by Europe. The main contributors are the presence of important players in the industry, the elevated level of attention to patients, the powerful presence of new products and the established health infrastructure.

Over the forecast period, Europe is expected to be the fastest developing region. Increased marketing and the existence of a big target population drive the IBS therapy market.

Players have adopted policies to boost their market share, such as extension of products, product growth, regional expansion, and fusions and acquisitions. In April 2015, the company purchased a portfolio focused on gastrointestinal medicines by Salix Pharmaceuticalals.

Irritable bowel syndrome is a gastrointestinal functional intestinal disorder which may be defined by contractions of the colon muscle. The big intestine is affected by irritable bowel syndrome. Irritable bowel syndrome is caused by bowel dysfunction and is mostly present in the elderly.

Key Players & Strategies

Some of the key players in the market are Allergan; Ironwood Pharmaceuticals, Inc.; Synergy Pharmaceuticals Inc., Bausch Health; Takeda Pharmaceutical Company Limited AstraZeneca; Sebela Pharmaceuticals Inc.; Synthetic Biologics, Inc.; Astellas Pharma, Inc.; and Ardelyx. The main players have adopted distinct approaches for increasing their market share, such as mergers and acquisitions. In April 2015, for example, Bausch Health purchased a portfolio of Salix Pharmaceuticals focusing on gastrointestinal medicine.

In order to expands its market presence, players are also focused on launching their products in distinct areas. Ironwood Pharmaceuticals and AstraZeneca obtained marketing permission for Linzess in China in January 2019, for example, to enhance their market position.

Request for Customization@ https://www.acumenresearchandconsulting.com/request-customization/1528

The report is readily available and can be dispatched immediately after payment confirmation.

Buy this premium research report – https://www.acumenresearchandconsulting.com/buy-now/0/1528

Would like to place an order or any question, please feel free to contact at sales@acumenresearchandconsulting.com | +1 407 915 4157

About Acumen Research and Consulting:

Acumen Research and Consulting (ARC) is a global provider of market intelligence and consulting services to information technology, investment, telecommunication, manufacturing, and consumer technology markets. ARC helps investment communities, IT professionals, and business executives to make fact based decisions on technology purchases and develop firm growth strategies to sustain market competition. With the team size of 100+ Analysts and collective industry experience of more than 200 years, Acumen Research and Consulting assures to deliver a combination of industry knowledge along with global and country level expertise.